Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...

Lotte Biologics announced on the 13th that it has signed a memorandum of understanding (MOU) for collaboration in the ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Blue Circle Health, a 501(c)(3) nonprofit organization dedicated to improving the health of people with type 1 diabetes (T1D), announced the expansion of its free, virtual, clinical care, education, ...

BOSTON, March 11, 2025 /CNW/ -- TraceLink ... This transformative two-day conference convened leading oncologists, primary... AbbVie today announced the final analysis of the confirmatory Phase 3 ...

The Boston-based biotech said today that the orally ... for antibody-based therapies from Biogen, Roche/Prothena and AbbVie. Inhibikase Therapeutics is meanwhile running early-stage trials of ...

Good day, and welcome to the Fourth Quarter 2024 Harvard Bioscience Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will be a ...

Leaders of three of these companies – Philadelphia’s Interius BioTherapeutics, Seattle’s Umoja BioPharma, and Boston’s Kelonia ... themselves – such as AbbVie, who are working with ...

Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral therapy (ART) avoided rebound for 5 months, a randomized trial showed. At 20 weeks from ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

AbbVie is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net ...